Background: Bleeding and thromboembolism continue to be the greatest cause of morbidity and mortality during extracorporeal membrane oxygenation (ECMO). The activated clotting time (ACT) remains a standard for heparin management in both ECMO and cardiopulmonary bypass (CPB), despite its weak correlation to the lower plasma heparin levels of ECMO. Furthermore, little is known about the hemostatic alterations related to ECMO versus CPB in children. We hypothesize that the hemostatic profile of ECMO patients differs significantly from those undergoing CPB, and furthermore that age-specific differences exist between neonatal and pediatric ECMO patients.

Methods: A prospective observational study evaluating antithrombin III (ATIII), fibrinolysis, thrombin generation, platelet activation and platelet response to agonist during CPB and ECMO at baseline, 4 and 24 hrs. Differences between age groups (neonatal vs. pediatric) in the ECMO group were also compared at baseline, 4, 12, 24, 72, and 144 hrs respectively.

Results: The ECMO group was younger, weighed less, and had a lower body surface index than the CPB group. There were significant differences in baseline ATIII levels, platelet
functionality, D-Dimer, and F1+2 concentrations between groups. Dichotomization of the ECMO group revealed that D-Dimer and F1+2 generation increased with time in neonatal patients.

**Conclusions:** ECMO generally had greater impact on the hemostatic system than CPB. Circulating platelets were less responsive and markers of fibrinolytic and coagulation activation were greater in the ECMO group at all 3 time points compared between the two therapies. Fibrinolytic and coagulation activation increased with time significantly in the neonatal ECMO population.
# TABLE OF CONTENTS

1.0 INTRODUCTION ........................................................................................................ 1

1.1 INDICATIONS & COMPLICATIONS ........................................................................ 1

1.2 PROTEIN ADSORPTION & PLATELET ACTIVITY ........................................... 5

1.3 CONTACT ACTIVATION & COAGULATION CASCADE ................................. 7

1.3.1 Extrinsic Cascade ......................................................................................... 8

1.3.2 Common Pathway ....................................................................................... 9

1.3.3 Fibrinolysis ................................................................................................. 10

1.3.4 Regulation of the Coagulation Cascade ...................................................... 12

1.3.5 Complement Activation ............................................................................... 13

1.4 ANTICOAGULATION IN ECMO ...................................................................... 15

1.5 MEASUREMENTS OF ANTICOAGULATION AND HEMOSTASIS .............. 17

1.5.1 Activated Clotting Time ......................................................................... 18

1.5.2 Activated Partial Thromboplastin Time ................................................. 19

1.5.3 Antithrombin III ...................................................................................... 21

1.5.4 Prothrombin Fragment 1+2 ................................................................. 22

1.5.5 D-Dimer .................................................................................................. 22

1.5.6 S100β ...................................................................................................... 24

1.5.7 Platelet Activation .................................................................................... 25
2.0 PATIENTS AND METHODS

2.1 PATIENT CRITERIA AND CIRCUIT SET-UP

2.2 BLOOD COLLECTION & ASSESSMENT OF CLOTTING TIMES

2.3 ASSESSMENT OF PLASMA MARKERS

2.4 ASSESSMENT OF PLATELET ACTIVATION AND AGGREGATION

2.5 ASSESSMENT OF GRANULOCYTE-PLATELET AGGREGATES

2.6 DATA & STATISTICAL ANALYSIS

3.0 RESULTS

4.0 DISCUSSION

BIBLIOGRAPHY
LIST OF TABLES

Table 1.1 Reasons for Respiratory ECMO Cannulation in Neonatal and Pediatric Patients. Included is the percent of the respiratory cases both internationally and at Children’s Hospital of Pittsburgh (CHP) along with the percent survival. Adapted from ECLS International Registry Report January 2011 [2]. ............................................................ 2

Table 1.2 Reasons for Cardiac ECMO Cannulation in Neonatal and Pediatric Patients. Included is the percent of the cardiac cases both internationally and at Children’s Hospital of Pittsburgh (CHP) along with the percent survival. Adapted from ECLS International Registry Report January 2011 [2]. ................................................................................. 3

Table 1.3 Complications encountered during ECMO. Included is the percent of the reported cases both internationally and at Children’s Hospital of Pittsburgh (CHP) along with the percent survival for each complication. Adapted from ECLS Registry Report January 2011 [2]. ............................................................................................................ 4

Table 1.4 Point of Care Tests. The ACT+, ACT-LR, and aPTT were each designed to detect different heparin doses based on the activator used in each test. ........................................... 19

Table 3.1. Patient Demographics .................................................................................................. 33

Table 3.2 Blood Product Administration (mL blood products/ kg patient/ hr) ......................... 36

Table 3.3 Point of Care Testing: Spearman Correlation.......................................................... 36
LIST OF FIGURES

Figure 1.1 Platelet Activation during ECMO. Upon platelet activation, platelets form cross bridges with fibrinogen that has deposited on the surface of circuit. Once activated, platelets release both $\alpha$ and dense granules into the environment activating even more platelets. ................................................................. 7

Figure 1.2 The Coagulation Cascade. ECMO activates the intrinsic part of the coagulation cascade via contact activation; however, the extrinsic portion can become activated due to tissue damage producing TF. ATIII is the primary naturally occurring anticoagulant and is therefore the target of many anticoagulants such as heparin.... 10

Figure 1.3 Fibrinolysis. The generation of thrombin in the ECMO circuit eventually results in fibrin clot formation, which is cleaved by plasmin, producing D-Dimer a marker of fibrinolysis................................................................. 11

Figure 3.1. Diagnosis for ECMO Patients......................................................... 34

Figure 3.2 Diagnosis for CPB Patients............................................................ 35

Figure 3.3: Antithrombin III Levels Comparing ECMO and CPB Patients at baseline, 4 hours post-cannulation and 24 post-op (CPB) or 24 hours on ECMO. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%) .................................................. 38

Figure 3.4 Antithrombin III Levels Comparing Neonatal and Pediatric ECMO Patients. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%) ....................... 39
Figure 3.5 D-Dimer Levels Comparing ECMO and CPB Patients at baseline, 4 hours post-cannulation and 24 post-op (CPB) or 24 hours on ECMO. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%).

Figure 3.6 D-Dimer Levels Comparing Neonatal and Pediatric ECMO Patients. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%).

Figure 3.7 F1+2 Levels Comparing ECMO and CPB Patients at baseline, 4 hours post-cannulation and 24 post-op (CPB) or 24 hours on ECMO. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%).

Figure 3.8 F1+2 Levels Comparing Neonatal and Pediatric ECMO Patients. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%). Significant differences were found between neonatal time indices.

Figure 3.9 Percent Platelet Activation (using P-selectin) Comparing ECMO and CPB Patients at baseline, 4 hours post-cannulation and 24 post-op (CPB) or 24 hours on ECMO. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%).

Figure 3.10 Percent of Granulocytes Positive for CD42b (Granulocyte-Platelet Aggregates) Comparing ECMO and CPB Patients at baseline, 4 hours post-cannulation and 24 post-op (CPB) or 24 hours on ECMO. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%).

Figure 3.11 Percent Platelet Activation (using P-selectin) Comparing Neonatal and Pediatric ECMO Patients. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%).
Figure 3.12 Percent of Granulocytes Positive for CD42b (Granulocyte-Platelet Aggregates) Comparing Neonatal and Pediatric ECMO Patients. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%). .......................................................... 46

Figure 3.13 Percent Platelet Activation with ADP Stimulation Comparing ECMO and CPB Patients at baseline, 4 hours post-cannulation and 24 post-op (CPB) or 24 hours on ECMO. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%). ................................................................................................................................... 47

Figure 3.14 Percent Platelet Activation with ADP Stimulation Comparing Neonatal and Pediatric ECMO Patients. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%). Significant differences were not found between neonatal and pediatric ECMO groups except at 144 hours. ........................................................................................................ 48

Figure 3.15 S100β Levels Comparing ECMO and CPB Patients at baseline, 4 hours post-cannulation and 24 post-op (CPB) or 24 hours on ECMO. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%). ............................................. 49

Figure 3.16 S100β Levels Comparing Neonatal and Pediatric ECMO Patients. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%). .......................................................... 50

Figure 3.17 S100β levels comparing one patient who experienced an intraventricular hemorrhage to an age-matched ECMO group (n=1 vs. n=8) ± standard deviation. The head ultrasound was performed every 2 days and the IVH was not detected until 504 hours on ECMO................................................................. 51
1.0 INTRODUCTION

Extracorporeal membrane oxygenation (ECMO) provides respiratory and cardiovascular support to neonatal (up to 30 days) and pediatric (30 days to 18 years) patients in cardiac and/or respiratory failure. Activation of the coagulation and inflammatory systems occurs when blood comes in contact with the ECMO circuit creating a need for systemic anticoagulation. Despite advances in circuit technology, including surface coatings and reduction in surface area and priming volumes, bleeding and thromboembolism remain the most common causes of morbidity and mortality for these patients [1].

1.1 INDICATIONS & COMPLICATIONS

Extracorporeal membrane oxygenation (ECMO) has been used to support more than 26,000 neonatal and pediatric patients over the last 25 years [2, 3]. ECMO is a modified form of cardiopulmonary bypass (CPB) that provides short-term (days to weeks) respiratory and cardiovascular support. It has been used successfully in both adults and children with the latter group having better outcomes [2]. The majority of neonatal patients are placed on ECMO for respiratory conditions (86% respiratory and 12% cardiac), whereas in pediatrics, the distribution is about equal (44% respiratory and 48% cardiac). As shown in Table 1.1, the most common respiratory uses for ECMO in neonatal patients are congenital diaphragmatic hernia (CDH),
meconium aspiration syndrome (MAS), persistent pulmonary hypertension of the newborn (PPHN)/persistent fetal circulation (FPC), respiratory distress syndromes (RDS) and sepsis. In pediatrics, ECMO is primarily used for pneumonia (viral, bacterial, and aspiration), ARDS (non post-operative), and acute respiratory failure (non-ARDS). Common cardiac reasons for ECMO support (see Table 1.2) include failure to wean from CPB after congenital heart defect repairs, cardiac arrest, cardiogenic shock, cardiomyopathy, and myocarditis. For most pediatric patients, ECMO may be the only option for respiratory or cardiovascular support since ventricular assist devices and other forms of mechanical circulatory support are only available for patients with larger surface areas.

Table 1.1 Reasons for Respiratory ECMO Cannulation in Neonatal and Pediatric Patients. Included is the percent of the respiratory cases both internationally and at Children’s Hospital of Pittsburgh (CHP) along with the percent survival. Adapted from ECLS International Registry Report January 2011 [2].

<table>
<thead>
<tr>
<th>Reason for Cannulation</th>
<th>Neonatal</th>
<th></th>
<th>Pediatric</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>International % Resp. Runs / CHP % Resp. Runs</td>
<td>International % Survival / CHP % Survival</td>
<td>Reason for Cannulation</td>
<td>International % Resp. Runs / CHP % Resp. Runs</td>
</tr>
<tr>
<td>CDH</td>
<td>25 / 30</td>
<td>51 / 41</td>
<td>Viral Pneumonia</td>
<td>20 / 28</td>
</tr>
<tr>
<td>MAS</td>
<td>31 / 30</td>
<td>94 / 88</td>
<td>Bacterial Pneumonia</td>
<td>11 / 6</td>
</tr>
<tr>
<td>PPHN/PFC</td>
<td>16 / 20</td>
<td>78 / 74</td>
<td>Aspiration Pneumonia</td>
<td>4 / 7</td>
</tr>
<tr>
<td>RDS</td>
<td>6 / 7</td>
<td>84 / 69</td>
<td>ARDS</td>
<td>8 / 3</td>
</tr>
<tr>
<td>Sepsis</td>
<td>11 / 4</td>
<td>75 / 59</td>
<td>Acute Resp. Failure</td>
<td>17 / 32</td>
</tr>
</tbody>
</table>
Table 1.2 Reasons for Cardiac ECMO Cannulation in Neonatal and Pediatric Patients. Included is the percent of the cardiac cases both internationally and at Children’s Hospital of Pittsburgh (CHP) along with the percent survival. Adapted from ECLS International Registry Report January 2011 [2].

<table>
<thead>
<tr>
<th>Reason for Cannulation</th>
<th>Neonatal</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>International % Cardiac Runs / CHP % Cardiac Runs</td>
<td>International % Cardiac Runs / CHP % Cardiac Runs</td>
</tr>
<tr>
<td>Congenital Defect</td>
<td>86 / 68</td>
<td>38 / 59</td>
</tr>
<tr>
<td>Cardiac Arrest</td>
<td>1 / 13</td>
<td>22 / 33</td>
</tr>
<tr>
<td>Cardiogenic Shock</td>
<td>1 / 0</td>
<td>39 / 0</td>
</tr>
<tr>
<td>Cardiomyopathy</td>
<td>2 / 5</td>
<td>62 / 80</td>
</tr>
<tr>
<td>Myocarditis</td>
<td>1 / 0</td>
<td>50 / 0</td>
</tr>
</tbody>
</table>

Although ECMO improves survival rates from less than 20% to nearly 80% in most cases, it is not without significant co-morbidities. In general, the most common complications for all ECMO patients are bleeding and thrombosis. Data from the 2011 ELSO registry [2] shown in Table 1.3 indicates that internationally the major complication for all children placed on ECMO regardless of the reason they were placed on ECMO is the need for inotropic agents. Additionally, the need for hemofiltration remains a major complication for all of these children. In the cardiac population, bleeding is a major complication while in the respiratory population it is not. It is interesting to note that according to the ECLS International Registry Report, neonates experience more thrombotic complications whereas pediatric patients experience more bleeding. Children’s Hospital of Pittsburgh (CHP) has similar types of complications, but the rates are much lower. One of the reasons our institution has fewer complications is that we are a higher
volume center. We have more institutional experience and routinely perform these procedures. Despite the reduced complications, CHP has a higher mortality for their respiratory patients. It is difficult to explain the difference and make a meaningful comparison without the severity of illness of the patients being placed on ECMO. The difference may be due to the fact that the children that CHP is willing to place on ECMO are more ill prior to being placed on ECMO, or that more sick children are going on ECMO because the critical care team is managing the possible ECMO children better thereby preventing the less sick children from ever being placed onto ECMO. Additionally, there may be discrepancies in the reporting of complications to the international ELSO registry. This may be due to the lack of formal definitions for each category or the lack of adjudication of the registry.

Table 1.3 Complications encountered during ECMO. Included is the percent of the reported cases both internationally and at Children’s Hospital of Pittsburgh (CHP) along with the percent survival for each complication. Adapted from ECLS Registry Report January 2011 [2].

<table>
<thead>
<tr>
<th>Complication</th>
<th>Neonatal</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Respiratory</td>
<td>Cardiac</td>
</tr>
<tr>
<td></td>
<td>% Reported</td>
<td>% Survived</td>
</tr>
<tr>
<td>Clots in oxygenator</td>
<td>17.4 / 5.9</td>
<td>65.0 / 30.0</td>
</tr>
<tr>
<td>Need for inotropes</td>
<td>19.7 / 9.4</td>
<td>61.0 / 42.0</td>
</tr>
<tr>
<td>Hemofiltration required</td>
<td>14.7 / 18.1</td>
<td>53.0 / 52.0</td>
</tr>
<tr>
<td>Surgical site bleeding</td>
<td>6.2 / 6.3</td>
<td>44.0 / 28.0</td>
</tr>
<tr>
<td>Cannula site bleeding</td>
<td>7.1 / 10.4</td>
<td>64.0 / 51.0</td>
</tr>
</tbody>
</table>
1.2 PROTEIN ADSORPTION & PLATELET ACTIVITY

Blood contact with a foreign surface results in rapid fibrinogen deposition, raising the local concentration more than 100-fold over the plasma concentration and provides a necessary ligand for platelet adhesion. Platelets do not bind directly to the surface of a material, but upon activation undergo a conformational change, which provides a binding site for fibrinogen (see Figure 1.1). Although fibrinogen deposition increases platelet adhesion, it is not required for platelet activation. Extracorporeal surface contact, thrombin, platelet activating factor, and heparin all contribute to platelet activation during ECMO. Non-activated platelets have a very low affinity for fibrinogen, and activation greatly increases their ability to be cross-linked with fibrinogen. In addition to fibrinogen, platelets have been shown to adhere to von Willebrand’s factor (vWF), fibronectin, fibrin, vitronectin, IgG, and plasma proteins containing the RGD sequence (arginine-glycine-aspartic acid). The local mechanical environment also impacts platelet adhesion. Zaidi et al. have shown that low to medium shear (250-800s⁻¹) result in adhesion of platelets to surface-bound fibrinogen while shear stresses higher than that result in adhesion to vWF [4]. Platelet adhesion can be diminished by masking the foreign surface with a more inert protein, such as albumin. Since albumin lacks the RGD sequence, platelet receptors do not recognize albumin. However, albumin must occupy at least 98% of the surface to exert these non-thrombogenic effects. In fact, fibrinogen adhesion over as little as 2% of a given surface area has been associated with platelet activation [5].

Circulating platelet concentration is typically 150-400x10⁹/L with an average lifespan of 7-10 days. Platelet membranes consist of a phospholipid bilayer integrated with surface receptors, including glycoprotein IIb/IIIa (GPIIb/IIIa) and GPIb. These receptors mediate the platelet-surface interactions (adhesion) and the platelet-platelet interactions (aggregation). The
platelet-phospholipid surface acts as a catalyst, selectively absorbing coagulation factors from the plasma. Platelets also contain 2 types of storage granules: (1) α-granules which contain platelet factor 4 (PF-4), β-thromboglobulin, and plasma proteins (fibrinogen, fibronectin, and Factors V and VIII), platelet derived growth factor (PDGF), P-selectin, and transforming growth factor α (TGF-α); (2) dense granules which contain adenosine diphosphate and triphosphate (ADP and ATP), serotonin, ionized calcium (Ca^{2+}), histamine and epinephrine [6].

When platelets become activated, they become “sticky” and develop pseudopodia. Activation also causes the platelets to contract (via actin and myosin) and release their storage granules into the environment (e.g. thromboxanes and ADP), which activate other platelets in a positive feedback fashion. In addition to platelet activation, platelet adhesion to the circuit occurs. It has been shown that upon initiation of CPB, a 40% platelet loss occurs within the first 5 minutes due to platelet adhesion to the surface and platelet aggregation [7]. As already discussed, GPIIb/IIIa is the platelet receptor that attaches to fibrinogen that has adhered to extracorporeal foreign surface, as well as vWF, fibronectin, fibrin, or vitronectin. GPIb acts as a surface receptor for vWF and also contributes to platelet adhesion to the foreign surface. Because of the ongoing platelet activation, most ECMO centers have adopted a policy of monitoring and maintaining platelet counts of at least 100,000/µL.
Figure 1.1 Platelet Activation during ECMO. Upon platelet activation, platelets form cross bridges with fibrinogen that has deposited on the surface of circuit. Once activated, platelets release both $\alpha$ and dense granules into the environment activating even more platelets.

1.3 CONTACT ACTIVATION & COAGULATION CASCADE

The normal process of blood activation occurs in two distinct pathways (extrinsic and intrinsic pathways) that converge to a common pathway (see Figure 1.2). During ECMO, activation is mostly triggered by the intrinsic pathway. Blood contact with a foreign surface results in activation of the intrinsic pathway where zymogens begin being cleaved into their active enzymes resulting in a cascade of events with the result being thrombin formation. Factor XII (Hageman factor), prekallikrein (PK), high molecular weight kininogen (HMWK), and Factor XI (FXI) comprise the four proteins responsible for this contact activation. FXII, PK, and XI are proenzymes that are converted to the active serine proteases, FXIIa, kallikrein (K), and FXIa.
presence of PK and HMWK, is converted to FXIIa, which is a weak neutrophil activating agonist that has three roles [8]. First, in the presence of HMWK and K, FXIIa activates FXI, which in turn activates the intrinsic pathway. Second, FXIIa cleaves PK to produce K, which feeds back to contribute to the activation of FXIa. Lastly, FXIIa cleaves HMWK to produce bradykinin, a strong vasodilator that may be responsible for this characteristic of the inflammatory response [8]. FXIa, in the presence of calcium, activates FIX, and the activated FIX, calcium, and FVIIIa form a complex on the surface of activated platelets and this complex comprises the tenase complex, whose role is to activate FX [9].

1.3.1 Extrinsic Cascade

Activation of the extrinsic system results from tissue damage, which exposes the blood to tissue factor (TF), a membrane protein present in the subendothelium. TF is not expressed on cells that normally come in contact with blood, but when tissue damage or inflammation occurs, it is the most potent trigger of blood coagulation. The process and continued state of cannulation necessary with ECMO may continually expose blood to the subendothelium and provide a source for TF expression. Even without tissue damage, the extrinsic system can still become mildly activated during ECMO by the expression of TF most likely released as a result of the inflammatory state. TF binds to FVII and the resulting TF/FVIIa complex activates FX. FXa may remain on the TF expressing cell, or diffuse into the blood and bind to activated platelets.
1.3.2 Common Pathway

Both FXa and already generated thrombin can activate FV. FXa, calcium, the phospholipid surface of platelets, and FVa comprise the prothrombinase complex that cleaves prothrombin to produce thrombin [10]. Calcium functions similarly to a cofactor, promoting the binding between enzyme, substrate, and other components [6]. The cleavage of prothrombin to thrombin is an important step in the common pathway because it produces protein fragment F1+2 that can be followed as a marker of coagulation activation. Thrombin can activate FV, FVIII, and platelets, as well as working on the substrates fibrinogen and FXIII. Therefore, once thrombin is generated, it initiates a potent positive feedback system that continues to produce more thrombin. The activation of FXIIIa works to stabilize the fibrin clot. The production of thrombin amplifies the already deleterious effects of blood activation by producing fibrin, further activating platelets, and stimulating the production of tissue factor plasminogen (tPa), which initiates fibrinolysis.
Figure 1.2 The Coagulation Cascade. ECMO activates the intrinsic part of the coagulation cascade via contact activation; however, the extrinsic portion can become activated due to tissue damage producing TF. ATIII is the primary naturally occurring anticoagulant and is therefore the target of many anticoagulants such as heparin.

1.3.3 Fibrinolysis

Activation of the coagulation cascade ultimately results in the conversion of fibrinogen to fibrin via thrombin generation. In addition, the production of fibrin initiates fibrinolysis, essentially breaking down the clot that has formed. A circulating plasma proenzyme, plasminogen, is converted to plasmin, the major fibrinolytic protease, by tissue plasminogen activator (tPA) or urokinase-like plasminogen activator (u-PA) [6]. tPA is synthesized by endothelial cells and is
released due to a number of stimuli including thrombin and bradykinin, and is the most important of the plasminogen activators [6, 11]. Once activated, plasmin cleaves available fibrin, resulting in fibrin fragments that will eventually be degraded and cleared from the blood. One such fragment includes D-Dimer, a noted marker of fibrinolysis (Figure 1.3) [6, 12]. In addition to cleaving fibrin, plasmin has also been shown to activate platelets, further stimulating the coagulation cascade [11]. Even though plasminogen is inactive and cannot cleave fibrin, its still has an affinity for fibrin and can become integrated into a fibrin clot.

Figure 1.3 Fibrinolysis. The generation of thrombin in the ECMO circuit eventually results in fibrin clot formation, which is cleaved by plasmin, producing D-Dimer a marker of fibrinolysis.

Because hemorrhagic complications are among the most common and result in increased morbidity and mortality, the use of aminocaproic acid (AMICAR) has been proposed to combat the bleeding complications in “high risk” patients. Pre-existing or anticipated surgical procedures while on ECMO, evidence of hypoxia or acidosis, prematurity, previous intracranial hemorrhage, and coagulopathy were common indicators for high-risk patients. In a 10 yr study from 1991 to 2001, the Children’s Hospital in Boston enrolled 431 patients, 298 of whom were deemed high
risk and given AMICAR [13]. This study found that there was a significant decrease in surgical site bleeding in the AMICAR group. However, overall survival rate, quantifiable bleeding, and transfusion requirement was not statistically significantly different between the AMICAR and control group. There was also no difference in thrombotic complications between the two groups, but the AMICAR groups did have a significant increase in circuit changes. In addition, the AMICAR group required a longer duration of ECMO support than the control group but it should be pointed out that this might be due to the fact that the patients were of higher risk. In the same study, thrombotic complications were compared in the AMICAR group and the control group. The results showed that there was no difference in cerebral infarction or large vessel thrombosis. Even though the results of the study concluded that AMICAR does not decrease the rate of ICH or improve the patients’ survival rate, it is still considered as an option to decrease surgical site bleeding.

1.3.4 Regulation of the Coagulation Cascade

Three inhibitory pathways regulate the coagulation system: the protein C pathway, the tissue factor pathway inhibitor (TFPI), and antithrombin III (ATIII). When thrombin binds to its endothelial receptor, thrombomodulin, it undergoes a conformational change at its active site that converts it from a procoagulant enzyme to activated protein C (APC) [14]. Using Protein S as a cofactor, APC acts as an anticoagulant by inactivating FVa and FVIIIa, which blocks thrombin generation [14]. TFPI is a regulatory protease inhibitor of the FVIIa/TF complex, which terminates the formation FXa and FIXa [15]. ATIII is a serine protease inhibitor that physiologically targets proteases in the intrinsic coagulation system. More specifically, ATIII has the ability to irreversibly inactivate Factors IIa (thrombin), IXa, Xa, XIa and XIIa making it the
most useful agent in reducing thrombotic activity [6]. ATIII is further discussed in the section on monitoring of anticoagulation and hemostasis.

1.3.5 Complement Activation

ECMO leads to activation of the systemic inflammatory response, which results from complement activation generated by the large foreign surface of the ECMO circuit. Complement activation results in cell lysis, production of inflammatory mediators that attract phagocytes, opsonization of organisms for clearance by phagocytosis, and enhancement of antibody-mediated immune responses. Similar to the coagulation cascade, complement proteins are created as zymogens and later cleaved to become active enzymes. These proteins can be activated via 3 pathways – the classical pathway, the lectin pathway, and the alternative pathway. However, during ECMO, the alternative pathway is predominantly activated.

The alternative pathway is activated when the C3 thioester bond spontaneously hydrolyzes in response to the activating surfaces, chemicals, or infectious agents. This is thought to occur because there is a slow tick-over of C3 to C3b occurring all of the time due to the instability of the C3 thioester bond. Hydrolyzed C3 binds to activated Factor B, and then Factor D cleaves Factor B (which is bound to hydrolyzed C3), thereby activating C3 convertase, which cleaves C3 to C3a and C3b. C3b, activates C5 convertase and also acts as an opsonin, targeting cell surfaces for recognition by macrophages and neutrophils. C5 convertase cleaves C5 into C5a and C5b. C6-9 sequentially bind to C5b and comprise the membrane attack complex (MAC), which inserts into the lipid wall of bacteria or eukaryotic cells and causes osmotic lysis. If assembly of C5b-9 takes place in the extracellular fluid, it is termed terminal complement complex (TCC). C5a and C3a are anaphylatoxins further stimulating the inflammatory response.
Anaphylatoxins are molecules that can bind to the receptor of many cell types and stimulate smooth muscle cell contraction, increase vascular permeability and activate mast cells to release inflammatory mediators. C5a is also chemotactic for monocytes and neutrophils, stimulating leukocyte adhesion to blood vessel walls.

Complement activation is similar in many different forms of extracorporeal circulation including CPB, dialysis, and plasmapheresis, due primarily to contact with a large artificial surface, which initiates the alternative pathway through autohydrolysis of C3 [16]. In fact off-pump cardiac surgery markedly reduces complement activation [17]. After 1 hour on ECMO, levels of C3a peaked and after 2 hours levels of C5a and terminal complement complex (TCC) peak [16, 18]. The C5a peak may be delayed as compared to the C3a peak since C5a has stronger binding to complement receptors [18]. In addition to an increase in complement activation, elastase and tumor necrosis factor α (TNFα) concentration are elevated [19]. It is hypothesized that the rapid increase in TNFα results because ECMO mobilizes preformed TNFα stores from the gut as opposed to the de novo generation of TNFα from leukocytes [20]. These cytokines are increased above the already elevated levels seen in critically ill patients prior to ECMO [17]. Complement and leukocyte activation remain elevated and then return to pre-ECMO levels after 24 hours [18, 19, 21].

In addition to the systemic inflammatory effects, the complement system directly impacts the coagulation system, enhancing the thrombogenicity of blood through at least four different mechanisms. The primary mechanism is the up-regulation of TF in leukocytes by the potent anaphylatoxin C5a. Therefore, although TF is normally only found deep in the adventitia and exposed upon vessel injury, interaction with a foreign surface can easily initiate the extrinsic pathway in the absence of any tissue damage. A second mechanism for increasing coagulation is
the assembly of the MAC, which increases the vascular permeability and can lead to exposure of the subendothelial layer, and consequently TF, and an increase in prothrombinase activity. Circulating mast cells are another source of increased thrombogenesis as a result of inflammation. They are among the first responders to sites of inflammation, and in addition to their phagocytic functions, mast cells contribute to the regulation of vasodilation by releasing factors such as histamine, prostaglandin D₂, vascular endothelial growth factor (VEGF), and TNF-α. Resting mast cells constitutively produce the serine protease, tPA, which is an initiator of fibrinolysis, without producing its counterbalance, PA inhibitor 1 (PAI-1) [22]. However, in vitro studies have shown that in the presence of C5a, mast cells begin producing more PAI-1 than tPA, switching from a pro-fibrinolytic state to an anti-fibrinolytic state [23]. Finally, components of the complement pathway can also increase coagulation by inhibiting regulators of the coagulation cascade. The C4b-binding protein (C4BP), a component of the classical complement pathway, can bind to Protein S, a cofactor of the Protein C anticoagulant pathway. This binding decreases the availability of Protein S to be used as a cofactor in the Protein C pathway [24].

1.4 ANTICOAGULATION IN ECMO

Because blood contact with the foreign surface of the ECMO circuit results in rapid thrombin formation, the natural anticoagulation processes are quickly overwhelmed, resulting in the need for systemic anticoagulation. Due to its widespread use during CPB and invasive vascular procedures, heparin is the predominant anticoagulant used during ECMO. Heparin functions as an anticoagulant by binding to the primary blood coagulation regulator ATIII with high affinity.
This induces a conformational change in ATIII, and increases its effective activity by 3-4 orders of magnitude. Heparin is advantageous for ECMO since it can be administered intravenously, has an immediate onset of action, and can be rapidly reversed by protamine if needed. Even though the discovery of heparin changed the treatment of thrombosis, there continues to be limitations associated with its use. For economical reasons, unfractionated heparin (UFH) is usually used, with only about one third of the administered dose actually containing the active heparin sulfate molecule to bind ATIII [25]. The remaining two-thirds of UFH has minimal anticoagulant effects at a therapeutic dose. In addition, the remaining two-thirds seems to be the portion of the heparin molecule that non specifically binds to platelets and cells leading to the unpredictable nature of the dose-response relationship [25]. UFH heparin has a plasma half-life of about 30 -150 minutes depending on the dose given and its effects not only vary between individuals but also between specific age groups such as neonatal and pediatric patients. The age-matched individual differences have been ascribed to non-specific endothelial and cell-surface protein binding of heparin, while the age-dependent effects are believed to result from differences in the levels and activity of various components of the blood between birth and approximately 6 months of age [26, 27, 28]. The anticoagulant activity of heparin is also limited to factors that are not surface-bound and therefore has no effect on thrombin bound to fibrin and FXa bound to a phospholipid surface [19]. Most importantly, with regards to ECMO, the use of heparin may lead to significant bleeding complications that may result in the discontinuation of ECMO. In some cases, heparin can lead to heparin-induced thrombocytopenia (HIT), which is a serious concern for adult patients following prior exposure to heparin and requires alternative anticoagulation therapies. If fractionated heparin, also called low molecular weight heparin (LMWH) is used, it only comprises the active one-third of the heparin molecule. LMWH was
developed primarily because of its superior pharmacologic properties including having reduced anti-IIa to anti-Xa ratio, more predictable anticoagulant response making monitoring of anticoagulation easier, longer plasma half-life, and reduced incidence of HIT and osteopenia [25]. Although there are reports on other anticoagulants used for patients on ECMO, it is beyond the scope of this study and will not be discussed here.

1.5 MEASUREMENTS OF ANTICOAGULATION AND HEMOSTASIS

Activation of the hemostatic system includes the vessel wall, platelets, blood coagulation and fibrinolysis. Some tests for monitoring anticoagulation and hemostasis are capable of monitoring all of these components at once making it difficult to determine the underlying coagulopathy or factor deficiency, or they only look at one specific part of the hemostatic system causing the need for it to be used in conjunction with other tests. In an ideal patient undergoing anticoagulation therapy, there would be no tissue damage or hypoxia, thrombocytopenia/thrombocytosis, platelet dysfunction, and no coagulation factor deficiencies or depletion of the naturally occurring anticoagulants. However, during ECMO it is not uncommon that more than one of these confounding factors is also present, presenting a major challenge when monitoring hemostasis. Despite the fact that there are many laboratory tests that can be done to look at the hemostatic profile as a whole, this is not often done and more commonly practitioners rely on a point of care (POC)/ bedside test due to its ease of use in the critical care setting. These POC test may not be specific enough to detect potential clotting or bleeding problems. Introducing more sensitive biomarkers to the battery of tests available to clinicians may enable earlier detection of potential adverse events before they matriculate.
1.5.1 Activated Clotting Time

The activated clotting time (ACT) has been used as a bedside monitoring tool for adequate ECMO anticoagulation because of its ease of use and long history in CPB patient management. Although other devices exist, the Hemochron Junior is commonly the device used in the acute critical care setting and it is capable of doing three common POC tests including the ACT+, the ACT-LR, and the aPTT. In general, all of these POC tests use the same mechanism. A cartridge contains an area where the whole blood sample is added and this blood can pass into one of two channels. Blood (15 µL) passes into the test channel and the remaining blood into the waste channel. The test channel contains an activator (see Table 1.4) that will promote blood coagulation. The activated blood passes through a series of LED optical detectors that are aligned with the test channel of the cuvette. The speed of the blood sample between detectors is measured until the blood stops and the ACT is reported in seconds.

The ACT has previously been reported to exhibit a poor correlation with heparin concentrations. Previous studies have shown weak to excellent correlations (ρ=0.38-0.98) between the weight-normalized heparin dose or plasma heparin levels and ACTs [29, 30, 31]. However, for ACT values less than 225 seconds there appears to be no correlation between the ACT and plasma heparin level (assessed by the anti-Xa assay) or the weight-normalized heparin dose [32, 33]. This is important with respect to ECMO because most institutional protocols maintain ACT values between 180 and 220 seconds, which may result in inadequate or over anticoagulation [30]. Further, significant hemodilution of hemostatic factors, activation of the hemostatic system, and activation of platelets occurs during ECMO and can affect whole blood tests such at the ACT [29]. Thus, the inadequacy of ACTs to effectively indicate anticoagulation status, particularly in neonatal and pediatric patients on ECMO, has increased the demand for an
alternative bedside anticoagulation test with an acceptable correlation to plasma heparin levels. To address this, a modified version of the ACT, the ACT-LR (low range), was created with the intended patient population being cardiac catheterization patients who require a milder state of anticoagulation. The ACT-LR was designed to monitor low-moderate heparin dosages by having a lower concentration of the same activators used in the traditional ACT, which is intended for use in CPB because it monitors moderate or high heparin doses. However, some centers continue to use the traditional ACT because they believe that it has a better reproducibility over time than the ACT-LR.

Table 1.4 Point of Care Tests. The ACT+, ACT-LR, and aPTT were each designed to detect different heparin doses based on the activator used in each test.

<table>
<thead>
<tr>
<th></th>
<th>ACT+</th>
<th>ACT-LR</th>
<th>aPTT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intended to Monitor</td>
<td>Moderate- High Heparin dose (1-6 IU/ml)</td>
<td>Low-Moderate Heparin dose (0-2.5 IU/ml)</td>
<td>Low Heparin dose (0-1.5 IU/ml)</td>
</tr>
<tr>
<td>Used in</td>
<td>CPB</td>
<td>ECMO &amp; Critical Care</td>
<td>ECMO &amp; Critical Care</td>
</tr>
<tr>
<td>Activators</td>
<td>Silica, kaolin, phospholipid</td>
<td>Lower concentration silica, kaolin, phospholipid</td>
<td>Glass, kaolin, phospholipid</td>
</tr>
</tbody>
</table>

1.5.2 Activated Partial Thromboplastin Time

Activated partial thromboplastin time (aPTT) is also used clinically as an alternative or complimentary indicator to ACTs to test for adequate anticoagulation. A major drawback to the aPTT test in critical care situations such as ECMO is the turnaround time for results since it is a
laboratory-based test. To address this, ITC introduced the POC aPTT. The POC aPTT was designed for use in ECMO and critical care because of its ability to monitor small changes in low heparin dosages due to the fact that it contains a weaker activator than both the ACT+ and the ACT-LR (see Table 1.4). The POC aPTT uses a conversion table programmed into the Hemochron Jr device to convert the whole blood POC aPTT to a plasma based lab aPTT. Since this conversion assumes a healthy adult individual with normal platelet count (150,000/µL) and normal coagulation factor levels, there will be discrepancies between the POC aPTT and the lab aPTT when these conditions are not met.

It has been shown that there is little correlation between ACTs and plasma heparin levels or ACTs with aPTTs. Several studies have shown a good linear correlation between the aPTT and plasma heparin concentrations up to 2.0 units/ml [32, 34, 35]; however, one study did demonstrate no correlation when specifically looking at pediatric patients treated for thromboembolism [36]. This may be due to components of the coagulation cascade being dependent on both gestational and postnatal age, resulting in infants having prolonged aPTT values that do not reach adult values until 3 months [37]. The POC aPTT has been shown to have varying correlation to the laboratory values, and is impacted by many factors including sampling technique, sample size, operator variability, and variations in sample processing [31]. The Hemochron Jr. whole blood POC PTT has previously been shown to correlate well (ρ=0.72) with plasma heparin levels (measured by the anti-Xa assay) in pediatric cardiac catheterization patients [38]. Caution should be taken when using the PTT as a sole indicator of anticoagulation or when comparing the POC PTT to the lab PTT. Since the lab PTT measures the generation of thrombin by the intrinsic pathway involving coagulation factors synthesized by the liver, patients on ECMO with liver dysfunction or chronic inflammation would be more likely to have
inaccurate PTT values. It is not uncommon in the ECMO population for patients to be septic or have some type of liver dysfunction. In addition, coagulation parameters constantly change over the first few weeks to months of life. These parameters are dependent on postnatal age in addition to gestational age resulting in infants having prolonged lab PTT values that do not reach adult values until 3 months [37]. Vitamin K factor (II, VII, IX, X) deficiencies, contact factor (XII, XI, PK, HMWK) deficiencies, as well as deficiencies in coagulation inhibitors (AT, Protein C), are believed to cause the altered lab PTT values [37].

1.5.3 Antithrombin III

In addition to measures of the “clotting times”, measurements of the concentrations of particular components of the clotting cascade can give insight into the relative production or breakdown of these components, which can in turn be correlated to the coagulation state of the patient. Antithrombin III (ATIII) irreversibly binds to and inactivates factors such as FXa, thrombin, and FVIIa. Since the absence (or depletion) of ATIII limits the effectiveness of heparin-based anticoagulation, it may be clinically important measure the ATIII levels of children on ECMO. Measurements are made using a chromogenic assay to quantitatively determine ATIII levels in plasma. Measurement of ATIII in the neonatal population has shown their levels are only 25% of normal adult levels; suggesting a possible reason for poor correlation between plasma heparin levels and measures of anticoagulation such as ACT and PTT [26, 28]. Some hospitals continuously infuse ATIII in ECMO patients, while others monitor ATIII levels and give fresh frozen plasma for reduced ATIII levels or concentrated ATIII for very low levels, while other institutions do not even use the ATIII to assist in developing the coagulation profile of ECMO.
patients. Depletion of ATIII during prolonged ECMO support may be responsible for the procoagulant state seen in patients days after the initial activation period [39].

1.5.4 Prothrombin Fragment 1+2

F1+2 is one of the fragments generated during the cleavage of prothrombin to thrombin and can be detected as a marker of thrombin generation. Although not FDA approved to be used clinically, F1+2 is frequently used in the literature to study thrombin in many aspects of medicine especially when investigating the hemostasis profiles in patient populations. Since this test is not used clinically and there are no standard normal values established to determine whether it is elevated, most studies use their own baseline F1+2 concentrations as a reference. Few studies have examined the F1+2 levels in ECMO patients. Urlesberger et al. found in a small study of 7 infants that F1+2 increased steeply in the first 2 hrs on ECMO followed by a slow decrease [39]. Even though the F1+2 began decreasing after 2 hrs, the D-Dimer remained high. They speculated that there were 2 possible reasons for the decreasing F1+2 despite a high D-Dimer. First, the half-life of D-Dimer is much longer (9 hr) than the half-life of F1+2 (90 min), and second, that fibrin dependent fibrinolysis is responsible for the D-Dimer levels remaining high [39].

1.5.5 D-Dimer

D-Dimer is a breakdown product of cross-linked fibrin, and has been used clinically as a marker of fibrinolysis. A D-Dimer test can be used to indicate that significant clot formation occurred
resulting in an increase in fibrinolysis to breakdown the clot. D-Dimer can also be a sign of a serious coagulation disorder called disseminated intravascular coagulopathy (DIC). Consumptive coagulopathy or disseminated intravascular coagulopathy (DIC) seems to occur in ECMO patients within the first 24 hours on ECMO. Consumptive coagulopathy occurs when you have increased activation of the coagulation pathway resulting in intravascular fibrin deposition, and depletion of coagulation proteins and platelets. This leads to 2 simultaneous events: bleeding and clotting. Normal D-Dimer values are not only age dependent but also dependent on the test method, meaning that normal values must be established for each lab. Pediatric D-Dimer normal values have been established by our institution to be between 0 - 0.499 µg/ml, which agrees with the results from other institutions [40], but no neonatal norms have been established. Consideration needs to be taken when using D-Dimer to measure fibrinolysis and it should be used in conjunction with other anticoagulation tests. High levels of D-Dimer are also seen with elevated rheumatoid factor (as seen in rheumatoid arthritis), high triglycerides, lipedemia, bilirubin and increased hemolysis.

Compared to adults, healthy, non-stressed neonates have been shown to have higher levels of D-Dimer within the first 24 hours of life, with stressed neonates having an even higher increase in thrombin generation [41, 42]. During the first 2 hours of ECMO, D-Dimer levels increase drastically accompanied by an increase in thrombin-antithrombin levels, low fibrinogen levels and low platelet counts, which can be interpreted as consumptive coagulopathy [39]. Tests indicative of DIC would include a prolonged PTT (due to consumption of coagulation proteins), decreased fibrinogen (due to its conversion to fibrin), increased D-Dimer (due to the increased fibrinolysis from an increase in clot formation), and a decreased platelet count (due to consumption of activated platelets within the clot). Although the consumptive coagulopathy
seems to improve after 24 hours, D-Dimer levels remain high for 48 hours before returning to baseline [39]. It has been suggested that the increase in D-Dimer in children on CPB is a result of tissue damage and/or inadequate anticoagulation [29].

1.5.6 S100β

The most serious end organ outcome resulting from bleeding/clotting complications in pediatric ECMO patients is brain damage. However, current diagnostic tools (e.g. CT scan, MRI, and ultrasound) only detect serious infarction or hemorrhage. Therefore, a sub-clinical marker of brain injury may be useful as an early measure of organ injury to initiate corrective action before irreversible damage occurs and to guide anticoagulation management. S100β has been proposed as an early marker for brain damage. This protein is not normally found in the plasma prior to stroke, subarachnoid hemorrhage, head injury or CPB [43]. S100β levels > 0.5 ng/mL are considered pathological in the adult population [44]. Previous studies have shown that detectable levels of S100β occur with the start of CPB in adults, and peak at CPB termination [45]. Conversely, coronary bypass or thoracic surgery without CPB does not increase S100β levels [44, 46]. Neonates and children younger than 8 years may have detectable levels of S100β protein in the blood prior to CPB without neurological damage (neonates can have S100β levels up to 2 ng/mL prior to CPB, and children can have levels up to about 1 ng/mL) [47]. It is hypothesized that this may be due to the fact that young children have a less selective blood-brain barrier combined with a high protein turnover in neural cells and decreased renal excretion [43, 47].
1.5.7 Platelet Activation

As previously described, platelet activation occurs when blood comes into contact with the foreign surface of the ECMO circuit. Platelets become activated, release granules, and express adhesion molecules such as P-selectin (CD62P) and CD63 [48]. Structural and functional changes have been reported in both the adult and pediatric population during CPB. However, our knowledge of platelet activation and dysfunction is more limited in the neonatal and pediatric ECMO population. In the adult CPB population platelets have been shown to have increased activation within minutes of the initiation of CPB and decreased responsiveness to ADP and collagen [49]. It has been shown that the platelets of adult CPB patients have an increased expression of P-selectin/CD62P [50]. P-selectin has been shown to increase in the first 5 minutes of CPB and peak at 120 minutes with activation 1.4 times greater than pre-CPB levels [50, 51]. It has been suggested that there may be a limit of P-selectin expression in the adult CPB population, because platelet activation is minimal, or that activated platelets are being removed from circulation, either by adhesion to the CPB circuit or in the lungs/spleen [50]. It has also been suggested that platelet-leukocyte aggregates are a more sensitive marker of platelet activation than P-selectin due to the fact that once platelets have degranulated, they may rapidly lose their surface P-selectin causing them to be undetected in circulation despite activation [52]. In patients who suffered from an acute myocardial infarction Michelson et al. showed that monocyte-platelet aggregates were a more sensitive marker of platelet activation than P-selectin [53].

In the neonatal CPB population, platelets have been shown to be hyporeactive in infants less than 2 months undergoing CPB when compared to children older than 12 months. The reason for this may be that platelets undergo an age-dependent maturation process that includes
less pseudopods, smaller glycogen deposits, less visible microtubular structures and less α-granules [48]. In a study by Robinson et al., platelet aggregation was studied in the newborn ECMO population using ADP, collagen, and ristocetin with time points pre-ECMO, the first few hours on ECMO, then 1 and 8 hours after coming off ECMO. There was no decrease in the ability of platelets to respond to collagen at any point during this study, but within 15 minutes on ECMO the platelet response to ADP and ristocetin decreased [49]. In addition, there was no change in surface expression of platelet glycoprotein Ib or IIa by flow cytometry [49]. In this study, we sought to investigate the neonatal and pediatric ECMO population, not only in terms of platelet response to agonist (ADP), but also platelet activation by using P-selectin.
2.0 PATIENTS AND METHODS

Given the current understanding of hemostatic alternations in pediatric and neonatal ECMO, we sought to evaluate such alterations and compare the observed parameters to a group of pediatric patients undergoing CPB for non-emergent cardiac surgery. To accomplish this objective, we utilized a prospective observations study to evaluate in these groups the activation of specific coagulation factors, platelet activation and response to agonists, and markers of organ dysfunction and early neurologic injury during ECMO and CPB.

2.1 PATIENT CRITERIA AND CIRCUIT SET-UP

This prospective study was approved by University of Pittsburgh Institutional Review Board and written informed consent was obtained from the parents of all participants. All children receiving ECMO for respiratory and/or cardiac failure were eligible for the study. Patients unable to separate from CPB or receiving ECMO within 48 hours of CPB were excluded due to prior exposure to heparin. Blood samples were taken prior to support (baseline), then at 4, 12, 24, and every 72 hours until the discontinuation of ECMO. Data was also collected from children undergoing elective cardiothoracic surgery (requiring CPB) to serve as population controls. Blood samples from these patients were taken prior to support, post CPB, and 24 hours post-
operatively. Blood product administration was also recorded for each time point and normalized according to the weight of the patient.

Patients in the ECMO group were supported by a roller pump (Stockert-Shiley S3, Sorin Group), with either 3/8” or 1/4” diameter tubing and an oxygenator. The decision to use the 3/8” circuit was based on patient weight (> 11.0 kg). The 1/4” circuit consisted of Carmeda® coated tubing and hollow fiber oxygenator (Minimax®, Medtronic), whereas the 3/8” circuit consisted of either Carmeda® bonded circuit with Affinity® hollow fiber oxygenator (Medtronic) or a Safeline™ bonded circuit with Quadrox D® non-porous diffusive membrane oxygenator (Maquet). Each 1/4” circuit was primed with 700 mL crystalloid solution with 1 unit of leukoreduced packed RBCs (pRBCs), 30 mL Tromethamine (Tham®) and 10 mL NaHCO₃ (volumes proportional to units of pRBCs used). A loading dose of heparin (50 U/kg) was given prior to cannulation to achieve an ACT > 300 sec. All patients were cannulated through the internal jugular vein and common carotid artery. Following initiation of support, a continuous heparin infusion (Unfractionated heparin, APP Pharmaceuticals) was started when the ACT was < 220 seconds and titrated to maintain an ACT of 160-200 seconds. During ECMO support, platelets and hematocrit were kept >100,000/cm³ and 30%, respectively, through blood, FFP, and cryoprecipitate transfusions.

Patients in the CPB group were induced with sevoflurane and maintained with isoflurane, fentanyl, midazolam and rocuronium. The bypass circuit and perfusion protocols were performed according to established institutional practices as described by Manrique et al [54].
2.2 BLOOD COLLECTION & ASSESSMENT OF CLOTTING TIMES

Baseline blood samples were collected from central venous or arterial access lines. Blood samples taken following initiation of ECMO or CPB blood were collected from a pre-heparin port on the circuit. All blood samples were 10 ml and were collected in 1.8 or 2.7 ml vacutainers containing 3.2% (0.109M) sodium citrate (Becton Dickenson, Franklin Lakes, NJ).

Point-of-care (POC) ACTs and aPTTs (Hemochron Jr®, International Technidyne Corporation), laboratory aPTTs (Diagnostica Stago), and weight normalized heparin administration were recorded throughout support and compared to plasma heparin levels measured by chromogenic anti-Xa determination (STA®-Rotachrom® Heparin kit, Diagnostica Stago).

2.3 ASSESSMENT OF PLASMA MARKERS

Plasma for immunoassays was extracted by centrifugation of blood samples at 2,000 x g for 15 minutes and stored at -80°C. Specific markers for activation of the clotting system were also measured: F1+2 (Enzyme-linked immunosorbant assay, Siemens), D-Dimer (Immuno-Turbidimetric Assay, Diagnostica Stago), and ATIII (Colorimetric Assay, Diagnostica Stago). In addition, serum S100β levels were also measured as a sub-clinical marker of brain injury (S100 enzyme-linked immunosorbant assay, International Point of Care). All assays were conducted according to manufacturer’s specifications.
2.4 ASSESSMENT OF PLATELET ACTIVATION AND AGGREGATION

Whole blood (5 µL) was transferred from sodium citrate Vacutainers into 12 x 75 mm polystyrene tubes (Falcon, Becton Dickinson) and incubated with 10 µL of each of the monoclonal antibody combinations: CD42b-FITC mixed with CD62P-PE and CD42b-FITC mixed with IgG1 Isotype Control-PE (BD Biosciences), and 25 µL of Phosphate Buffered Saline (PBS, Lonza) with 1% Bovine Serum Albumin (BSA, Fraction V, Sigma). Platelet activation was also assessed after stimulation with adenosine diphosphate (ADP). These samples were prepared as above with 5 µL of 200 µM ADP (EMD Biosciences), 5 µL of 20 mM glycine-proline-arginine-proline (GPRP, Anaspec) to inhibit fibrin polymerization, and 15 µL of PBS with 1% BSA (incubation buffer). All samples were incubated for 20 minutes in the dark with occasional gentle mixing. After incubation, samples were washed with 1 mL of PBS with 1% BSA buffer, centrifuged at 400 x g for 10 minutes, and fixed with 500 µL of 1% paraformaldehyde. Fixed samples were refrigerated at 4°C and analyzed by flow cytometry within 24 hrs. Platelets were identified by their characteristic forward scatter (FSC) and CD42b expression by a FACScan flow cytometer (Becton Dickinson) and a gate was set to collect 5000 single platelet events. Activation was defined by setting a threshold at 2% isotype control expression, a standard flow cytometric technique.

2.5 ASSESSMENT OF GRANULOCYTE-PLATELET AGGREGATES

As described above, whole blood (100 µL) was incubated with 10 µL of each of the monoclonal antibody combinations: CD42b-FITC/CD16-PE and IgG1 Isotype Control-FITC/CD16-PE (BD
Biosciences) and 80 µL of incubation buffer for 20 minutes in the dark with occasional gentle mixing. Following incubation, 2 mL of ACK buffer was added to lyse the RBCs. Samples were centrifuged at 400 x g for 10 min, and washed and fixed as described above. Ten thousand GPA (identified by their FSC and CD16 expression) events were collected. The threshold for granulocytes binding platelets was defined by setting a threshold at 2% isotype control expression. Granulocyte-platelet aggregates were similarly measured with CD16 population that was also positive for CD42b.

2.6 DATA & STATISTICAL ANALYSIS

Since it has been well documented that the neonatal plasma is deficient in many coagulation factors and inhibitors [35], and that neonatal platelets are hyporeactive [46], relative to pediatric patients, the figures and statistical analysis were split into these groups as well as the CPB group. Samples were collected until the end of ECMO. However, after 6 days on ECMO, the number of patients decreased to less than half of the sample population, and therefore only data within the first 6 days is presented.

ACT, lab PTT, POC PTT, and anti-Xa were analyzed using Spearman’s ranked correlation statistics (SPSS v18.0). POC PTTs that were greater than 250 sec and lab PTTs that were greater than 200 sec were excluded from the analysis as they were determined to be out-of-range by the measuring devices. CPB patient data was also excluded from the POC analysis since the heparin dose given during CPB was so much greater than ever used in ECMO. Some other limitations of the tests used included anti-Xa levels <0.10 IU/ml, which were given the value 0.09 IU/ml, D-Dimer levels <0.22 µg/ml which were given the value 0.21µg/ml, D-Dimer
> 20 μg/ml were given the value 21 μg/ml to be conservative. Therapeutic institutional norms for anti-Xa were established to be between 0.35 and 0.70 IU/ml. Pediatric D-Dimer normal values were established by our institution to be between 0 - 0.499 μg/ml in accordance with other institutions [37], but no neonatal norms have been established. D-Dimer values < 0.21μg/ml were only seen in CPB patients, and values >20 μg/ml were only seen in the ECMO population. Surprisingly, 2/3 of our anti-Xa values for ECMO patients only were less than 0.10 IU/ml. ATIII levels never fell out of range, and F1+2 and S100β were diluted to fall within range of the standard if needed. All tests were repeated if the coefficient of variance between the duplicate samples were >15% except in the bedside tests because they were not run in duplicate. Due to the fact that the groups were considered independent from each other and the data is not normally distributed, Mann-Whitney rank sum was used and all data are presented as median and IQ range (25%-75%).
3.0 RESULTS

Blood samples were collected from 22 ECMO patients (3 cardiac, 19 respiratory). Fourteen patients were neonates (<30 days) while the remaining eight were pediatric patients (30 days – 18 years). The ECMO group was younger, weighed less, and had a lower body surface index compared to the CPB control group, as shown in Table 3.1.

Table 3.1. Patient Demographics

<table>
<thead>
<tr>
<th>Variable</th>
<th>ECMO</th>
<th>CPB</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (Months)</td>
<td>0.28</td>
<td>21.85</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>[0.07 – 1.67]</td>
<td>[8.07 – 53.63]</td>
<td></td>
</tr>
<tr>
<td>Male Gender</td>
<td>45.5% (10)</td>
<td>66.7% (12)</td>
<td>0.153</td>
</tr>
<tr>
<td>Weight (Kg)</td>
<td>3.73</td>
<td>11.85</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>[2.62 – 6.00]</td>
<td>[7.10 – 17.50]</td>
<td></td>
</tr>
<tr>
<td>Body Surface Area (m²)</td>
<td>0.24</td>
<td>0.52</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>[0.19 – 0.32]</td>
<td>[0.37 – 0.72]</td>
<td></td>
</tr>
<tr>
<td>Duration of Support (Hours)</td>
<td>161.50</td>
<td>1.03</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>[106.0 – 366.0]</td>
<td>[0.83 – 1.33]</td>
<td></td>
</tr>
</tbody>
</table>
Reasons for ECMO cannulation are shown in Figure 3.1 and included pulmonary hypertension (n=8), infectious respiratory disease (n=5), heart failure (n=3), congenital diaphragmatic hernia (n=3), and acute respiratory failure (n=3). The reason for the unequal distribution of cardiac and respiratory cases was the inability to obtain a baseline sample from the cardiac population. Reasons for CPB cannulation are shown in Figure 3.2 and include atrial septal defect (n=6), atrial septal defect/ventricle septal defect (n=5), right outflow tract obstruction (n=4), and other conditions requiring elective cardiac surgery (n=3).

![Figure 3.1. Diagnosis for ECMO Patients](image)
Blood product administration was also recorded for each time point and then normalized according to the weight of the patient. The majority of the blood products—fresh frozen plasma (FFP), platelets, and packed RBCs—were administered in the beginning of ECMO and administration decreased as time on ECMO increased (Table 3.2).
Table 3.2 Blood Product Administration (mL blood products/ kg patient/ hr)

<table>
<thead>
<tr>
<th>Blood Product (mL/kg/hr)</th>
<th>0-4 hrs</th>
<th>4-12 hrs</th>
<th>12-24 hrs</th>
<th>24-72 hrs</th>
<th>72-144 hrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cryoprecipitate</td>
<td>0</td>
<td>0</td>
<td>0.45 ± 0.09</td>
<td>0.13 ± 0.08</td>
<td>0.16 ± 0.14</td>
</tr>
<tr>
<td>FFP</td>
<td>4.38 ± 1.55</td>
<td>2.38 ± 0.85</td>
<td>1.36 ± 0.40</td>
<td>0.41 ± 0.26</td>
<td>0.27 ± 0.14</td>
</tr>
<tr>
<td>Platelets</td>
<td>3.35 ± 1.25</td>
<td>2.44 ± 1.54</td>
<td>1.14 ± 0.48</td>
<td>0.82 ± 0.58</td>
<td>0.88 ± 0.43</td>
</tr>
<tr>
<td>pRBCs</td>
<td>3.73 ± 2.78</td>
<td>1.91 ± 1.25</td>
<td>0.95 ± 0.29</td>
<td>0.53 ± 0.42</td>
<td>0.60 ± 0.46</td>
</tr>
</tbody>
</table>

In terms of bedside testing the ACT had no correlation to plasma heparin levels (r=-0.016; p=0.44), while the lab PTT and POC PTT had a weak correlation to plasma heparin levels (r=0.44 and r=0.31 respectively) with p<0.001 as shown in Table 3.3.

Table 3.3 Point of Care Testing: Spearman Correlation

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Anti Factor Xa vs. ACT (Lab)</th>
<th>Anti Factor Xa vs. aPTT (Point of Care)</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (XY Pairs)</td>
<td>107</td>
<td>117</td>
</tr>
<tr>
<td>Spearman r (r_s)</td>
<td>-0.016</td>
<td>0.44</td>
</tr>
<tr>
<td>[95% CI]</td>
<td>[-0.21 – 0.18]</td>
<td>[0.28 – 0.58]</td>
</tr>
<tr>
<td>p value</td>
<td>0.44</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.001</td>
</tr>
</tbody>
</table>
Antithrombin III concentration for the ECMO population was low at baseline when compared to the mean normal neonatal (39-87 µg/ml) and pediatric (80-120 µg/ml) ATIII concentrations for our institution. In fact, when comparing the baseline ECMO patient average to the CPB patient average, the CPB patient had over 2 times greater ATIII concentration (Figure 3.3). The initiation of CPB resulted in a significant (p< 0.001) decrease in ATIII from baseline, while the initiation of ECMO did not. Twenty four hours post support, ATIII levels returned to baseline for the CPB population whereas in the ECMO population the values remained low despite FFP infusions in both groups. Comparing the neonatal and pediatric ECMO population there is a significant difference between the 2 age groups at baseline, then at 24 hours, 72 hours, and 144 hours (Figure 3.4).
Figure 3.3: Antithrombin III Levels Comparing ECMO and CPB Patients at baseline, 4 hours post-cannulation and 24 post-op (CPB) or 24 hours on ECMO. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%).
Figure 3.4 Antithrombin III Levels Comparing Neonatal and Pediatric ECMO Patients. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%).

D-Dimer concentration was elevated in the ECMO population prior to cannulation and did not significantly change at 4 hours, but peaked at 24 hours (p<0.05) as shown in Figure 3.5. The CPB population had low D-Dimer levels prior to cannulation, and at 4 hours, which increased at 24 hours (p<0.002). When comparing the neonatal and pediatric age groups, there were no significant changes in D-Dimer levels between any of the pediatric patients at any time. However, each hour except 4 hours post-cannulation was significantly higher (p values ≤ 0.05 as shown in Figure 3.6) than baseline in the neonatal ECMO population.
Figure 3.5 D-Dimer Levels Comparing ECMO and CPB Patients at baseline, 4 hours post-cannulation and 24 post-op (CPB) or 24 hours on ECMO. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%).
The F1+2 thrombin generation baseline levels were higher in the ECMO population than the CPB population (p=0.002) as shown in Figure 3.7. At 4 hours, there was no difference between the ECMO and CPB group, nor was there a significant change from baseline in either group. The ECMO patients had higher thrombin levels than CPB patients at 24 hours (p=0.002), but not significantly higher than baseline. At 24 hours, the CPB patients experienced higher thrombin levels than at baseline or 4 hours (p=0.003). After 4 hours on ECMO, neonatal patients had significantly higher thrombin levels from baseline, whereas the pediatric patients did not (Figure 3.8).
Figure 3.7 F1+2 Levels Comparing ECMO and CPB Patients at baseline, 4 hours post-cannulation and 24 post-op (CPB) or 24 hours on ECMO. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%).
Figure 3.8 F1+2 Levels Comparing Neonatal and Pediatric ECMO Patients. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%). Significant differences were found between neonatal time indices.

Platelet activation was similar for the ECMO and CPB groups prior to cannulation, but at 4 hours the CPB patients experience higher platelet activation as shown in Figure 3.9 (p=0.001) and Figure 3.10 (p<0.05). At 24 hours, the CPB group continues to have higher platelet activation than the ECMO group, but still not significantly higher than baseline as shown in Figure 3.9 (p<0.05). Comparing the ECMO subgroups, there didn’t appear to be a difference between the neonatal and pediatric children on ECMO (Figure 3.11 and Figure 3.12). When platelets were stimulated with ADP, CPB patients maintained a higher percent of functional platelets than did the ECMO patients at baseline, 4 hours, and 24 hours (p<0.05) as shown in
Figure 3.13. There did not appear to be a difference in platelet activation between the neonatal and pediatric ECMO groups (Figure 3.14). Therefore, in terms of platelet activation and dysfunction, CPB patients had more percent platelet activation and more functional platelets as compared to the ECMO group, and there did not appear to be a difference between the neonatal and pediatric ECMO patients in either platelets activation or functionality.

Figure 3.9 Percent Platelet Activation (using P-selectin) Comparing ECMO and CPB Patients at baseline, 4 hours post-cannulation and 24 post-op (CPB) or 24 hours on ECMO. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%).
Figure 3.10 Percent of Granulocytes Positive for CD42b (Granulocyte-Platelet Aggregates) Comparing ECMO and CPB Patients at baseline, 4 hours post-cannulation and 24 post-op (CPB) or 24 hours on ECMO. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%).
Figure 3.11 Percent Platelet Activation (using P-selectin) Comparing Neonatal and Pediatric ECMO Patients. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%).

Figure 3.12 Percent of Granulocytes Positive for CD42b (Granulocyte-Platelet Aggregates) Comparing Neonatal and Pediatric ECMO Patients. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%).
Figure 3.13 Percent Platelet Activation with ADP Stimulation Comparing ECMO and CPB Patients at baseline, 4 hours post-cannulation and 24 post-op (CPB) or 24 hours on ECMO. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%).
In this study prior to support, children going on ECMO had significantly higher S100β levels than CPB patients (p=0.007) as shown in Figure 3.15. At 4 hours, there was no difference between the ECMO and CPB groups, but the CPB patients had increased S100β levels from baseline (p<0.001). At 24 hours, S100β levels in CPB patients returned to baseline, significantly lower than the ECMO patients (p<0.001). Unlike other studies, when we separated out the neonatal and pediatric ECMO patients who did not experience an intraventricular hemorrhage (IVH), there were no differences between groups, nor were there differences as the time on ECMO increased (Figure 3.16). In this study, only one patient experienced an IVH. In Figure 3.17, this patient was separated and compared to the age-matched pediatric ECMO group. The S100β concentration for this patient was higher than the age-matched pediatric ECMO group.
who did not incur neurologic damage. It should be noted here that it is our institutional practice to perform a head ultrasound every 2 days, and that the ultrasound did not pick up the IVH until Day 21 on ECMO despite increased S100β levels from 24 hours and on.

Figure 3.15 S100β Levels Comparing ECMO and CPB Patients at baseline, 4 hours post-cannulation and 24 post-op (CPB) or 24 hours on ECMO. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%).
Figure 3.16 S100β Levels Comparing Neonatal and Pediatric ECMO Patients. Mann-Whitney Rank Sum: Presented at Median and IQ Range (25%-75%).
Figure 3.17 S100β levels comparing one patient who experienced an intraventricular hemorrhage to an age-matched ECMO group (n=1 vs. n=8) ± standard deviation. The head ultrasound was performed every 2 days and the IVH was not detected until 504 hours on ECMO.
4.0 DISCUSSION

In this relatively small, controlled study evaluating differences in hemostatic values for children who require ECMO compared to those undergoing elective repair of septal defects, we demonstrated that children requiring ECMO had significantly lower ATIII concentrations, increased D-Dimer concentrations, and that F1+2 thrombin generation increased substantially during the first 24 hrs. Antithrombin III was low, not only prior to ECMO support, but throughout support despite FFP and sometimes concentrated ATIII transfusions. Since ATIII is the primary blood coagulation regulator and the target of heparin, ATIII insufficiency is a likely cause of “heparin resistance”. It has been documented that heparin resistance is common (10-20%) during CPB and hypothesized that ATIII deficiency is most likely the cause of this resistance [55]. Traditionally, heparin dose is increased in response to suspected heparin resistance; however this will not only be ineffective in managing the heparin resistance but may also lead to an increase in thrombosis formation [55]. Inadequate anticoagulation secondary to low levels of ATIII, regardless of etiology may be partially responsible for fibrin generation and subsequent fibrinolysis, and should be considered an important component to monitor during ECMO. Taken collectively with increased baseline D-Dimer and F1+2 in the ECMO population, our study validates the suggestion by Urlesberger et al. that ECMO fits the pattern of consumptive coagulopathy; however, we did not see the improvement in consumptive coagulopathy after 24 hours as they did; rather, ATIII remained low, and D-Dimer and F1+2
remained high throughout the course of ECMO. In the Urlesberger et al. study a continuous ATIII infusion (73 ± 10 IU/kg/24 hours) was administered to maintain stable ATIII levels (0.63 ± 0.12 IU/mL). Fibrinogen concentrate and FFP was also administered to maintain fibrinogen levels greater than 0.8 gm/L, whereas in this study ATIII was not continuously infused and FFP was only given per clinician discretion (average of 8.07 ± 1.73 mL/kg/24 hours). This supports the hypothesis that ATIII deficiency may be contributing to the prolonged consumptive coagulopathy state.

The ECMO population had significantly less platelet activation than the CPB group in the first 24 hours of the beginning of ECMO. The platelets of ECMO patients were also less activated following stimulation with ADP as compared to the CPB group, including the baseline sample. The fact that the platelets had less ability to become activated by ADP in the ECMO group as compared to the CPB group suggests that it may be a combination of both decreased platelet functionality due to the underlying disease state of the child (especially at baseline) and adhesion of functional platelets to the circuit. This is supported by Weerasinghe et al. who suggested that the decreased P-selectin expression during CPB may be due to minimal platelet activation or removal of activated platelets from circulation, either by adhesion to the CPB circuit or in the lungs and spleen [50]. In the CPB group, it is difficult to ascertain whether the increased platelet activation is due to the high shear stresses encountered during CPB (including mechanical activation of platelets through the cardiotomy reservoir and the use of suction or the surgical procedure), or whether the preserved functionality of the platelets (from healthier pre-operative CPB patients) is allowing them to become more activated when compared to the ECMO group. Additionally, there may be increased platelet deposition in ECMO (as noted above) leaving less functional platelets to circulate. Unlike other studies [48] who have shown
that the platelets of infants undergoing CPB are hyporeactive when compared to older children, when we separated the neonatal from the pediatric patients, there was no difference between the age groups when using P-selectin or granulocyte platelet aggregates as well as no difference in the ability to become activated with ADP between the age groups. As time on ECMO increases, platelet activation does not appear to increase either. This may be due to the rapid deposition of platelets to the circuit within the first few minutes as previously described [7].

We further demonstrated that the current standard practice of monitoring only ACTs may not be sufficient in monitoring anticoagulation during ECMO. All cumulative anticoagulation tests failed to correlate well with plasma heparin levels. The ACT is used exclusively in 80% of the 81 active neonatal ECMO centers and showed no correlation to plasma heparin levels [13]. The aPTT on the other hand demonstrated a mild correlation to plasma heparin levels. It should be noted here that the lack of a strong correlation with plasma heparin levels does not preclude their use as an effective anticoagulation test. The ACT, which uses a more potent stimulant of coagulation, is designed to give an essentially binary indication of anticoagulation, which includes coagulation factor levels, platelet activation and dysfunction, and plasma heparin levels. Despite the lack of strong correlation, the POC aPTT showed better correlation to plasma heparin levels than the ACT. This may be due to the weaker stimulant used in the POC aPTT cartridge allowing for a more sensitive indication of heparin dose. Although not a bedside test, the laboratory measures of aPTT had the highest correlation to plasma heparin levels. This is useful since the turnaround time on the lab aPTT is not as long as some of the other laboratory hemostatic tests. The lab aPTT utilizes only plasma as opposed to whole blood, and are therefore independent of platelets. Therefore correlating these tests with each other (the POC aPTT and the lab aPTT), or simply with the plasma heparin levels may be difficult if platelet
activation/dysfunction and coagulation factor deficiencies are present as in patients on ECMO. These tests should be used in tandem and with other clinically available tests (e.g. ATIII, D-Dimer) presented here in order to examine the entire hemostatic profile of the patient.

We assume that the presence or absence of “neurologic injury” is the ultimate observational outcome. The low incidence of neurological insult in this study makes it difficult to draw conclusions with regard to outcomes; however, we did demonstrate that ECMO patients have higher S100β levels when compared to CPB patients prior to cannulation, but that the start of CPB increases S100β whereas ECMO does not. Similarly to adults, S100β levels peak at CPB termination [45] and then decrease by 24 hours post cannulation. Although neonates and children may have detectable levels of S100β prior to CPB [47], we did not find a difference between the two groups. The neonatal patients did exhibit higher levels of S100β, but it was not statistically significant nor did it reach a pathological level (>2 ng/mL). This may be because neonates have a less selective blood brain barrier, increased neural cell turnover and decreased renal excretion causing a artificially high level of S100β in the plasma without neurological damage [43, 47], or that low S100β levels throughout ECMO were indicative of preserved neurological function. Only one patient throughout the study developed any documented neurological damage. Head ultrasounds were performed on our patients every 2 days while on ECMO and one patient developed an IVH (detected by ultrasound) 21 days (504 hours) after the initiation of ECMO. When the S100β levels of this patient were age matched to the other ECMO pediatric patients in this study who did not develop an IVH, it was found that the S100β levels were 37 times higher than the age matched group and above the pediatric pathological level (>1 ng/mL) at least 15 days prior to detection by the ultrasound. Despite the low incidence of neurological insult, and given the evidence cited in this paper and throughout literature, it appears that the S100β may
still be a useful tool in the early detection of neurologic damage for children in both the ECMO and CPB population.

From this study, we suggest that the ECMO patient is in a state reflective of ongoing hemostatic activation prior to cannulation with high thrombin generation and fibrinolysis, low ATIII levels, and dysfunctional platelets. Further, we found that this state does not seem to improve while on ECMO. CPB activates more platelets, but produces less thrombin and fibrinolysis; this is most likely due to the high heparin dose, higher level of ATIII, and overall decreased severity of illness. Furthermore, this study validated other reports that weak correlations exist between clotting time (ACT) and heparin dose or heparin levels [32,33] illustrating the need for a cadre of assays to understand and monitor the function of the hemostatic system during pediatric ECMO. The use of other hemostatic tests, such as aPTT, ATIII, and anti-Xa may reduce the incidence of bleeding and thromboembolic events during ECMO.

This study was based on the observation that bleeding and thromboembolism remain significant co-morbidities associated with ECMO despite attempts to effectively anticoagulate the patient. Prior to this study, patients in the neonatal and pediatric intensive care units, like most ECMO centers, were monitored almost solely by the ACT to determine anticoagulation status of the patient. The goal of this study was to not only explain the hemostatic profile of the ECMO patient, but also illustrate other assays that could be used alongside the POC tests to develop a better understanding of the hemostatic system as a whole. As a consequence of the patient population, there are some limitations of the study. First, this study attempted to age-match the ECMO and CPB patients; however, during the two years of patient enrollment, all of the patients undergoing elective CPB were in the pediatric age group and significantly older,
while the majority of patients undergoing ECMO were neonatal patients (70%). Another important limitation of this study is the multiple comparisons made in clinical studies, which increases the likelihood that the data is found significant by chance (type I error). It is important to keep in mind that when a p-value approaches the upper limit of being statistically significant ($\alpha = 0.05$), there is less confidence that the difference did not occur by chance alone. While the Bonferroni correction can account for this discrepancy, this correction was not performed in this study due to the low number of multiple comparisons being made. Another limitation is the relatively low number of participants in each group, which could fail to reveal significant differences (type II error). While other clinical studies may be able to enroll many patients across different institutions and centers for common procedures, ECMO is reserved for the sickest patient population which limits the potential study enrollment pool. For future work, in order to determine a better statistical relationship between the ECMO and CPB group and between age groups within the ECMO population, a higher N is needed in each of the groups which would require a longer time of patient enrollment than was available for this project, or the inclusion of other medical centers. Other metrics may also be required, including length of stay, outcomes, severity of illness, and individual measures of other organ function to stratify these patients.
BIBLIOGRAPHY


